<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Summary of IUIS classification groups for inborn errors of immunity (primary immunodeficiencies)&lt;sup&gt;[1-3]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Summary of IUIS classification groups for inborn errors of immunity (primary immunodeficiencies)<sup>[1-3]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Summary of IUIS classification groups for inborn errors of immunity (primary immunodeficiencies)<sup>[1-3]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup> <colgroup width="20%"></colgroup> <colgroup width="10%"></colgroup> <colgroup span="2" width="30"></colgroup> <tbody> <tr> <td class="subtitle1">IUIS classification group</td> <td class="subtitle1">IEI disease category</td> <td class="subtitle1">Number of genes*</td> <td class="subtitle1">Characteristics</td> <td class="subtitle1">Examples</td> </tr> <tr> <td class="centered">I</td> <td>Cellular and humoral immunodeficiencies</td> <td class="centered">66</td> <td> <ul> <li>Recurrent viral, fungal, and bacterial infections </li> <li>Autoimmunity </li> </ul> </td> <td> <ul> <li>SCID </li> <li>DOCK8 deficiency </li> <li>CD40L deficiency </li> <li>MHC I/II deficiency </li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td class="centered">II</td> <td>Syndromic combined immunodeficiencies</td> <td class="centered">69</td> <td> <ul> <li>Recurrent viral, fungal, and bacterial infections </li> <li>Autoimmunity </li> <li>Nonimmune features </li> <li>Dysmorphology </li> </ul> </td> <td> <ul> <li>Hyper-IgE (STAT3) </li> <li>Wiskott-Aldrich syndrome </li> <li>Cartilage-hair hypoplasia </li> <li>22q11.2 deletion syndrome </li> <li>NEMO deficiency </li> </ul> </td> </tr> <tr> <td class="centered">III</td> <td>Antibody deficiencies</td> <td class="centered">45</td> <td> <ul> <li>Recurrent bacterial sinopulmonary infections </li> </ul> </td> <td> <ul> <li>X-linked (BTK) and autosomal recessive agammaglobulinemia </li> <li>Autosomal recessive hyper-IgM </li> <li>Selective IgA deficiency </li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td class="centered">IV</td> <td>Immune dysregulatory diseases</td> <td class="centered">52</td> <td> <ul> <li>Lymphoproliferation </li> <li>Autoimmunity </li> <li>Hemophagocytic lymphohistiocytosis </li> </ul> </td> <td> <ul> <li>Chediak-Higashi syndrome </li> <li>Perforin deficiency </li> <li>ALPS </li> <li>STAT3 gain of function </li> <li>CTLA4 deficiency </li> <li>LRBA deficiency </li> <li>IL-10 deficiency </li> </ul> </td> </tr> <tr> <td class="centered">V</td> <td>Phagocytic diseases</td> <td class="centered">42</td> <td> <ul> <li>Severe bacterial infections of the skin, lungs, and lymph nodes </li> <li>Inflammatory bowel disease </li> </ul> </td> <td> <ul> <li>Chronic granulomatous disease </li> <li>Leukocyte adhesion deficiency </li> <li>GATA2 deficiency </li> <li>Congenital neutropenias </li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td class="centered">VI</td> <td>Innate immunodeficiencies</td> <td class="centered">74</td> <td> <ul> <li>Invasive bacterial infections (sepsis, meningitis) often in the absence of fever </li> <li>Recurrent fungal, mycobacterial, and viral infections </li> </ul> </td> <td> <ul> <li>IRAK4 and MyD88 deficiency </li> <li>STAT1 gain of function </li> <li>Interferon gamma receptor deficiency </li> <li>IRF7 deficiency </li> <li>TLR3 deficiency </li> </ul> </td> </tr> <tr> <td class="centered">VII</td> <td>Autoinflammatory diseases</td> <td class="centered">56</td> <td> <ul> <li>Recurrent fever, rash, arthritis/arthralgia </li> <li>Amyloidosis </li> <li>Inflammatory bowel disease </li> </ul> </td> <td> <ul> <li>Familial Mediterranean fever </li> <li>Mevalonate kinase deficiency </li> <li>Muckle-Wells syndrome </li> <li>NLRP1 deficiency </li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td class="centered">VIII</td> <td>Complement deficiencies</td> <td class="centered">36</td> <td> <ul> <li>Disseminated neisserial infections </li> <li>Recurrent pyogenic infections </li> <li>SLE </li> <li>Atypical hemolytic uremic syndrome </li> </ul> </td> <td> <ul> <li>Deficiency of complement components (C1 to C9) </li> <li>Properdin deficiency </li> <li>Factor D deficiency </li> <li>Factor H deficiency </li> </ul> </td> </tr> <tr> <td class="centered">IX</td> <td>Bone marrow failure</td> <td class="centered">44</td> <td> <ul> <li>Macrocytic anemia and other cytopenias </li> <li>Skeletal, nail, hair, and/or skin abnormalities </li> </ul> </td> <td> <ul> <li>Fanconi anemia </li> <li>Dyskeratosis congenita </li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td class="centered">X</td> <td>Phenocopies of primary immunodeficiencies</td> <td class="centered">15</td> <td> <ul> <li>Various phenotypes </li> </ul> </td> <td> <ul> <li>ALPS-SFAS (somatic mutations in <em>TNFRSF6</em>) </li> <li>Mucocutaneous candidiasis due to autoantibodies to IL-17 or IL-22 </li> <li>Mycobacterial infections due to autoantibodies to IL-6 </li> <li>Acquired angioedema due to autoantibodies to C1 inhibitor</li> <li>Severe, life-threatening infections with SARS-CoV-2 due to autoantibodies to type 1 interferons (IFN-alpha and IFN-omega)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Summary of the major classification groups in the 2022 IUIS report.<sup>[3]</sup></div><div class="graphic_footnotes"><p>IUIS: International Union of Immunological Societies; 
        IEI: inborn errors of immunity; 
        SCID: severe combined immunodeficiency; 
        DOCK8: dedicator of cytokinesis 8; 
        CD40L: CD40 ligand; 
        MHC: major histocompatibility complex; 
        IgE: immunoglobulin E; 
        STAT3: signal transducer and activator of transcription 3; 
        NEMO: nuclear factor-kappa-B essential modifier; 
        BTK: Bruton tyrosine kinase; 
        IgM: immunoglobulin M; 
        IgA: immunoglobulin A; 
        ALPS: autoimmune lymphoproliferative syndrome; 
        CTLA4: cytotoxic T lymphocyte-associated antigen 4; 
        LRBA: lipopolysaccharide-responsive beige-like anchor; 
        IL: interleukin; GATA2: GATA-binding protein 2; 
        IRAK4: IL-1 receptor-associated kinase 4; 
        MyD88: myeloid differentiation primary response protein 88; 
        STAT1: signal transducer and activator of transcription 1; 
        IRF7: interferon regulatory factor 7; 
        TLR3: toll-like receptor 3; 
        NLRP1: NLR family pyrin domain-containing 1; 
        SLE: systemic lupus erythematosus; 
        ALPS-SFAS: autoimmune lymphoproliferative syndrome due to somatic <em>FAS</em> mutation; 
        <em>TNFRSF6</em>: tumor necrosis factor receptor superfamily member 6; 
        SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; 
        IFN: interferon.</p>
    
    * Number of genes as of May 2022.</div><div class="graphic_reference">References:
    <ol>
<li>Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol 2018; 38:96.</li>
<li>Yu JE, Orange JS, Demirdag YY. New primary immunodeficiency diseases: Context and future. Curr Opin Pediatr 2018; 30:806.</li>
<li>Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; epub.</li>
</ol></div><div id="graphicVersion">Graphic 121770 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
